1.80

1.10% -0.02

After Hours: 1.84 0.04 +2.22%

Gain Therapeutics Inc (GANX)

Overview News Price History Option Chain Financials Why GANX Down? Discussions Forecast

Gain Therapeutics Inc stock is traded at $1.80, with a volume of 200.83K. It is down -1.10% in the last 24 hours and up +2.27% over the past month. Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Previous Close:

$1.82

Open:

$1.81

24h Volume:

200.83K

Relative Volume:

0.27

Market Cap:

$78.56M

Revenue:

$55,200

Net Income/Loss:

$-21.24M

P/E Ratio:

-3.0586

EPS:

-0.5885

Net Cash Flow:

$-19.37M

1W Performance:

+1.69%

1M Performance:

+2.27%

6M Performance:

-29.96%

1Y Performance:

+3.45%

1-Day Range:

$1.785

$1.83

1-Week Range:

$1.75

$1.846

52-Week Range:

$1.53

$4.34

Gain Therapeutics Inc Stock (GANX) Company Profile

Name

Gain Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(301) 500-1556

Address

4800 HAMPDEN LANE, BETHESDA

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

GANX's Discussions on Twitter

Compare GANX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GANX Gain Therapeutics Inc	1.80	86.41M	55,200	-21.24M	-19.37M	-0.5885
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-06-24	Initiated	ROTH MKM	Buy
Aug-14-24	Resumed	Oppenheimer	Outperform
Apr-12-21	Initiated	BTIG Research	Buy
Apr-12-21	Initiated	Oppenheimer	Outperform

Gain Therapeutics Inc Stock (GANX) Latest News

Sep 01, 2026

Gain Therapeutics Inc (NASDAQ: GANX) Share Price, GANX Stock News, GANX Share Price & Updates - kalkine.ca

Sep 01, 2026

Aug 31, 2026

H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Aug 31, 2026

Aug 25, 2026

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network

Aug 25, 2026

Aug 19, 2026

Gain (GANX) Financial Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; After Results: The Stock Gains 1.97% on the DayEarnings Surprise Stocks - vinanet.vn

Aug 19, 2026

Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 19, 2026

Aug 18, 2026

Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Charm Flow - vinanet.vn

Aug 18, 2026

GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX - MarketBeat

Aug 18, 2026

Aug 15, 2026

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Aug 15, 2026

Aug 14, 2026

Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 14, 2026

Aug 13, 2026